Back to News & Events

EQUITY CROWDFUNDING WORKSHOP

As we all know, outside capital is like oxygen for technology related companies. Looking to raise funds to build your company? Equity crowdfunding may be an attractive option for startups or even companies of significant size (including those who have already done some capital raising!)

Join the Center for Biotechnology, Farrell Fritz, P.C.and the Long Island High Technology Incubator for a workshop led by Alon Kapen, JD, Partner at Farrell Fritz, P.C. and Chair of its Emerging Companies and Venture Capital practice group. Mr. Kapen will discuss different types of equity crowdfunding available and key considerations for companies contemplating a crowdfunding offering.

Topics will include costs, benefits, and drawbacks of different types of crowdfunding, including accredited crowdfunding under Rule 506(c) of Regulation D; non-accredited crowdfunding under Title III of the JOBS Act and Regulation Crowdfunding; and “mini” public offerings under “Regulation A+”.

Thursday, February 7, 2019 | 9am-10am
Long Island High Technology Incubator
Main Conference Room.
25 Health Sciences Drive, Stony Brook, NY 11790
Registration is free – please RSVP here.
https://cfb-equity-crowdfunding19.eventbrite.com

 


About our speaker: Mr. Kapen has extensive experience in providing focused representation to founders, startups, emerging companies, angel investors and venture capital funds in a wide range of high growth entrepreneurial matters and transactions.

Farrell Fritz is a full service law firm of more than 85 attorneys that has earned a strong reputation in the New York business community. The firm handles legal matters in the areas of bankruptcy & restructuring; business divorce; commercial litigation; condemnation & eminent domain; construction; corporate & finance; distressed assets; eDiscovery; emerging companies & venture capital; environmental law; estate litigation; health law; labor & employment; land use, municipal & zoning; real estate; tax planning & controversy; tax certiorari and trusts & estates for corporations, not-for-profit organizations and individuals.


The Long Island High Technology Incubator (LIHTI) is a non-profit organization dedicated to helping new technologically-innovative companies grow by providing them with a variety of support resources and services. Since its opening in 1992, the Incubator has been associated with more than 120 businesses, and over 60 companies have graduated successfully from the LIHTI program, contributing over $2.5B to the national economy and creating jobs for over 500 employees. Our affiliation with the Stony Brook University makes LIHTI an ideal place for cutting-edge R&D. Transferring technology and ideas from the University to the private sector has proven to be the single most important reason why the program has succeeded beyond anyone’s imagination.

 

Related Stories

WP_Query Object
(
    [query] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
        )

    [query_vars] => Array
        (
            [post_type] => post
            [posts_per_page] => 3
            [post_status] => publish
            [orderby] => rand
            [error] => 
            [m] => 
            [p] => 0
            [post_parent] => 
            [subpost] => 
            [subpost_id] => 
            [attachment] => 
            [attachment_id] => 0
            [name] => 
            [pagename] => 
            [page_id] => 0
            [second] => 
            [minute] => 
            [hour] => 
            [day] => 0
            [monthnum] => 0
            [year] => 0
            [w] => 0
            [category_name] => 
            [tag] => 
            [cat] => 
            [tag_id] => 
            [author] => 
            [author_name] => 
            [feed] => 
            [tb] => 
            [paged] => 0
            [meta_key] => 
            [meta_value] => 
            [preview] => 
            [s] => 
            [sentence] => 
            [title] => 
            [fields] => 
            [menu_order] => 
            [embed] => 
            [category__in] => Array
                (
                )

            [category__not_in] => Array
                (
                )

            [category__and] => Array
                (
                )

            [post__in] => Array
                (
                )

            [post__not_in] => Array
                (
                )

            [post_name__in] => Array
                (
                )

            [tag__in] => Array
                (
                )

            [tag__not_in] => Array
                (
                )

            [tag__and] => Array
                (
                )

            [tag_slug__in] => Array
                (
                )

            [tag_slug__and] => Array
                (
                )

            [post_parent__in] => Array
                (
                )

            [post_parent__not_in] => Array
                (
                )

            [author__in] => Array
                (
                )

            [author__not_in] => Array
                (
                )

            [search_columns] => Array
                (
                )

            [ignore_sticky_posts] => 
            [suppress_filters] => 
            [cache_results] => 1
            [update_post_term_cache] => 1
            [update_menu_item_cache] => 
            [lazy_load_term_meta] => 1
            [update_post_meta_cache] => 1
            [nopaging] => 
            [comments_per_page] => 50
            [no_found_rows] => 
            [order] => 
        )

    [tax_query] => WP_Tax_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => AND
            [table_aliases:protected] => Array
                (
                )

            [queried_terms] => Array
                (
                )

            [primary_table] => wp_posts
            [primary_id_column] => ID
        )

    [meta_query] => WP_Meta_Query Object
        (
            [queries] => Array
                (
                )

            [relation] => 
            [meta_table] => 
            [meta_id_column] => 
            [primary_table] => 
            [primary_id_column] => 
            [table_aliases:protected] => Array
                (
                )

            [clauses:protected] => Array
                (
                )

            [has_or_relation:protected] => 
        )

    [date_query] => 
    [request] => SELECT SQL_CALC_FOUND_ROWS  wp_posts.ID
					 FROM wp_posts 
					 WHERE 1=1  AND wp_posts.post_type = 'post' AND ((wp_posts.post_status = 'publish'))
					 
					 ORDER BY RAND()
					 LIMIT 0, 3
    [posts] => Array
        (
            [0] => WP_Post Object
                (
                    [ID] => 4439
                    [post_author] => 3
                    [post_date] => 2024-07-30 15:29:07
                    [post_date_gmt] => 2024-07-30 19:29:07
                    [post_content] => 

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [1] => WP_Post Object ( [ID] => 1592 [post_author] => 1 [post_date] => 2015-05-08 13:40:05 [post_date_gmt] => 2015-05-08 13:40:05 [post_content] => [post_title] => Long Island Bioscience Hub [post_excerpt] => The Center for Biotechnology has received a National Institutes of Health Research And Commercialization Hub award to establish the Long Island Bioscience Hub (LIBH) in collaboration with Stony Brook University, Cold Spring Harbor Laboratory and Brookhaven National Laboratory. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => long-island-bioscience-hub [to_ping] => [pinged] => [post_modified] => 2015-05-12 16:30:56 [post_modified_gmt] => 2015-05-12 16:30:56 [post_content_filtered] => [post_parent] => 0 [guid] => http://centerforbiotechnology.org/new/?p=1592 [menu_order] => 202 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [2] => WP_Post Object ( [ID] => 3912 [post_author] => 3 [post_date] => 2022-08-22 13:06:25 [post_date_gmt] => 2022-08-22 13:06:25 [post_content] =>

November 2-3, 2022 | Virtual

The Life Sciences Summit is an exclusive early stage investor and business development conference that highlights innovation. The objective of the event is to provide an intimate setting allowing emerging biotech companies and academic innovators to connect with the capital and strategic partners they will need to move new discoveries through clinical development.

The virtual 2022 program features thought provoking plenary sessions, presentations by promising young companies with transformative science, the "innovation pipeline" featuring academic innovators and pre-seed stage companies working on cutting edge technologies, and 1:1 networking opportunities.

View full details onlifesciencessummit.org

[post_title] => Save the Date! LSS 2022 [post_excerpt] => Join the Center for Biotechnology November 2-3 at our Virtual Life Sciences Summit 2022! [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => save-the-date-lss-2022 [to_ping] => [pinged] => [post_modified] => 2022-12-13 17:04:15 [post_modified_gmt] => 2022-12-13 17:04:15 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3912 [menu_order] => 23 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [3] => WP_Post Object ( [ID] => 3290 [post_author] => 3 [post_date] => 2019-07-18 19:14:24 [post_date_gmt] => 2019-07-18 19:14:24 [post_content] => Phase 0 Proof-of-Concept Partnership pilot program demonstrates effectiveness for transitioning basic science discoveries into the commercialization pipeline. The Long Island Bioscience Hub (LIBH), a National Institutes of Health (NIH) Research Evaluation and Commercialization Hub (REACH), is pleased to announce it has demonstrated significant impact as outlined in a recent evaluative report presenting the results and activities of the NIH REACH program over the pilot period of three years. The LIBH, a collaboration between Stony Brook University, Brookhaven National Laboratory, Cold Spring Harbor Laboratory, and the Feinstein Institute at Northwell Health, led by the Center for Biotechnology, was formed in March 2015 with a mission to help commercialize biomedical technologies emerging from the region’s research institutions. The report, prepared independently by RTI International on behalf of the NIH, outlines multiple outcomes from the REACH program, and documents the successes that the LIBH has had during the relatively short pilot phase of its work. The LIBH engaged 600 innovators in training sponsored or co-sponsored by the REACH Program. Fifty technology development projects have been funded by LIBH over the course of three years, including technologies focused on biologic drugs, diagnostic devices, small molecule drugs, therapeutic devices, and Health IT among others. As a result of the NIH investment in the LIBH, ten startup companies have been formed and two license agreements have been executed. In addition, the initial investment made by NIH in the region has generated follow on funding of more than $10 million, $2.8 million coming from five funded SBIR/STTR proposals based on LIBH technologies. This impact from the REACH program contributes to the overall economic impact of Center for Biotechnology, notably $1.2B over a recent fifteen year period. “We are thrilled with the outcomes reported in the RTI evaluation for the Long Island Bioscience Hub’s efforts thus far under the REACH program” said Clinton T. Rubin, Ph.D., Distinguished Professor, Department of Biomedical Engineering, and Director, Center for Biotechnology. “Through the REACH program we’ve been able to expand on the region’s efforts to commercialize more innovation locally, thereby capturing more of the economic impact within the region. While the pilot program will end in mid-2019, these impacts clearly demonstrate the potential of the model to make significant contributions to our innovation ecosystem.” “The RTI evaluation reinforces our knowledge that the Long Island Bioscience Hub model has already had a significant, positive impact on technologies and innovators embedded in our research community” stated Dr. Richard Reeder, Vice President for Research at Stony Brook University. “It is imperative we continue to fuel the activities of the LIBH as it is an essential part of innovation economy, and is a significant engine in bringing lifesaving technologies to patients.” The Center for Biotechnology, in collaboration with other partners in the region, will continue to explore how the model might be continued and expanded. Click here for PDF version. [post_title] => Long Island Bioscience Hub Reports Significant Impacts [post_excerpt] => The Long Island Bioscience Hub, is pleased to announce it has demonstrated significant impact as outlined in a recent evaluative report presenting the results and activities of the NIH REACH program over the pilot period of three years. [post_status] => publish [comment_status] => open [ping_status] => open [post_password] => [post_name] => news-libh-impacts [to_ping] => [pinged] => https://centerforbiotechnology.org/who-we-are/long-island-bioscience-hub/ [post_modified] => 2019-07-18 19:15:46 [post_modified_gmt] => 2019-07-18 19:15:46 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=3290 [menu_order] => 93 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) ) [post_count] => 4 [current_post] => -1 [before_loop] => 1 [in_the_loop] => [post] => WP_Post Object ( [ID] => 4439 [post_author] => 3 [post_date] => 2024-07-30 15:29:07 [post_date_gmt] => 2024-07-30 19:29:07 [post_content] =>

CFB Client, IAMBIC has been awarded approximately $1M in grant funding from the National Science Foundation Small Business Innovation Research program. IAMBIC is an innovative shoe company disrupting the centuries-old footwear industry with their sizeless, precision-fit footwear driven by proprietary AI algorithms. This substantial funding from NSF enables IAMBIC to scale its cutting-edge precision-fit shoe design and manufacturing.

The Center for Biotechnology and its accelerator programs have been instrumental in assisting IAMBIC with their SBIR pursuits and commercialization development.

Read more about IAMBIC and their recent funding here.

[post_title] => IAMBIC Receives $1 Million NSF SBIR Phase II Grant [post_excerpt] => This substantial funding from NSF enables IAMBIC to scale its operations. [post_status] => publish [comment_status] => closed [ping_status] => closed [post_password] => [post_name] => iambic-receives-1-million-nsf-sbir-phase-ii-grant [to_ping] => [pinged] => [post_modified] => 2024-08-09 15:38:43 [post_modified_gmt] => 2024-08-09 19:38:43 [post_content_filtered] => [post_parent] => 0 [guid] => https://centerforbiotechnology.org/?p=4439 [menu_order] => 0 [post_type] => post [post_mime_type] => [comment_count] => 0 [filter] => raw ) [comment_count] => 0 [current_comment] => -1 [found_posts] => 260 [max_num_pages] => 87 [max_num_comment_pages] => 0 [is_single] => [is_preview] => [is_page] => [is_archive] => [is_date] => [is_year] => [is_month] => [is_day] => [is_time] => [is_author] => [is_category] => [is_tag] => [is_tax] => [is_search] => [is_feed] => [is_comment_feed] => [is_trackback] => [is_home] => 1 [is_privacy_policy] => [is_404] => [is_embed] => [is_paged] => [is_admin] => [is_attachment] => [is_singular] => [is_robots] => [is_favicon] => [is_posts_page] => [is_post_type_archive] => [query_vars_hash:WP_Query:private] => 325c4f9f1aebaa5ec90666fa54175ba0 [query_vars_changed:WP_Query:private] => [thumbnails_cached] => [allow_query_attachment_by_filename:protected] => [stopwords:WP_Query:private] => [compat_fields:WP_Query:private] => Array ( [0] => query_vars_hash [1] => query_vars_changed ) [compat_methods:WP_Query:private] => Array ( [0] => init_query_flags [1] => parse_tax_query ) )

IAMBIC Receives $1 Million NSF SBIR Phase II Grant

More Information

Long Island Bioscience Hub

More Information

Save the Date! LSS 2022

More Information

Long Island Bioscience Hub Reports Significant Impacts

More Information